CTSK and osteoporosis: Recently, a large multinational, randomized, double-blind phase III study of odanacatib (a cathepsin K inhibitor) in postmenopausal women with osteoporosis was completed.[16] Both thyroid hormone and cathepsin K were closely related to bone maintenance and disease, for example, osteoporosis.